Objectives:

• 1. Explain the impact of patient-to-patient variation in the clinical effectiveness of drug combinations for advanced cancers
  2. Compare principles of combination therapy between curative-intent versus non-curative treatment settings
  3. Evaluate the effectiveness of adding a drug to regimens in the first-line versus second-line of care when the same agent is approved in both settings

Zoom info:

Join from PC, Mac, iPad, or Android: https://uwmadison.zoom.us/s/91224356041?pwd=74bE7MijOVPsRC9U5zaBadeGCtJ977.1; Passcode:145901

Phone one-tap: +19292056099,,91224356041# US (New York) 13017158592,,91224356041#; +(Washington DC); 

Join via audio: +1 929 205 6099 US (New York); +1 301 715 8592 US (Washington DC); +1 305 224 1968 US; +1 309 205 3325 US; +1 312 626 6799 US (Chicago); +1 646 931 3860 US; +1 564 217 2000 US; +1 669 444 9171 US; +1 669 900 6833 US (San Jose); +1 689 278 1000 US; +1 719 359 4580 US; +1 253 205 0468 US; +1 253 215 8782 US (Tacoma); +1 346 248 7799 US (Houston); +1 360 209 5623 US; +1 386 347 5053 US; +1 507 473 4847 US

Webinar ID: 912 2435 6041

International numbers available: https://uwmadison.zoom.us/u/acdfJxwPay

Join from an H.323/SIP room system: H.323: 144.195.19.161 (US West) or 206.247.11.121 (US East) Meeting ID: 912 2435 6041; Passcode: 145901

SIP: [email protected]; Passcode: 145901